Version 1
: Received: 1 October 2020 / Approved: 2 October 2020 / Online: 2 October 2020 (15:21:34 CEST)
Version 2
: Received: 10 December 2020 / Approved: 11 December 2020 / Online: 11 December 2020 (18:12:38 CET)
Version 3
: Received: 16 February 2021 / Approved: 17 February 2021 / Online: 17 February 2021 (12:58:18 CET)
How to cite:
KP, M.; Wlochowitz, D.; Wingender, E.; Beißbarth, T.; KEL, A. IGFBP2 is a Potential Master-Regulator Driving Dysregulated Gene Network Responsible for Short Survival in Glioblastoma Multiforme. Preprints2020, 2020100046. https://doi.org/10.20944/preprints202010.0046.v1
KP, M.; Wlochowitz, D.; Wingender, E.; Beißbarth, T.; KEL, A. IGFBP2 is a Potential Master-Regulator Driving Dysregulated Gene Network Responsible for Short Survival in Glioblastoma Multiforme. Preprints 2020, 2020100046. https://doi.org/10.20944/preprints202010.0046.v1
KP, M.; Wlochowitz, D.; Wingender, E.; Beißbarth, T.; KEL, A. IGFBP2 is a Potential Master-Regulator Driving Dysregulated Gene Network Responsible for Short Survival in Glioblastoma Multiforme. Preprints2020, 2020100046. https://doi.org/10.20944/preprints202010.0046.v1
APA Style
KP, M., Wlochowitz, D., Wingender, E., Beißbarth, T., & KEL, A. (2020). IGFBP2 is a Potential Master-Regulator Driving Dysregulated Gene Network Responsible for Short Survival in Glioblastoma Multiforme. Preprints. https://doi.org/10.20944/preprints202010.0046.v1
Chicago/Turabian Style
KP, M., Tim Beißbarth and ALEXANDER KEL. 2020 "IGFBP2 is a Potential Master-Regulator Driving Dysregulated Gene Network Responsible for Short Survival in Glioblastoma Multiforme" Preprints. https://doi.org/10.20944/preprints202010.0046.v1
Abstract
Only 2% of Glioblastoma multiforme (GBM) patients respond to standard care and survive beyond 36 months (long-term survivors, LTS) while the majority survives less than 12 months (short-term survivors, STS). To understand the mechanism leading to poor survival, we analyzed publicly available datasets of 113 STS and 58 LTS. This analysis revealed 198 differentially expressed genes (DEGs) that co-occur with aggressive tumor growth and may be responsible for the poor prognosis. These genes belong largely to the GO-categories “epithelial to mesenchymal transition” and “response to hypoxia”. Promoter and network analysis of the DEGs identified 5 potential master regulators that may explain dysregulation of the DEGs in the STS. The following 5 important master-regulators were identified: IGFBP2, VEGFA, PDGFA, OSMR and AEBP1. It is known that IGFBP2 confers increasing malignancy leading to poor prognosis. However, the molecular mechanism by which IGFBP2 affects disease progression and patient prognosis is unclear. Here we found that IGFBP2 is highly upregulated in short survivors and significantly impact survival. Further investigation of the gene regulatory network revealed that IGFBP2 expression can be regulated by FRA-1 transcription factor via MEK2/RAF/ERK5 pathway. FRA-1 is found to be upregulated and to have significant impact on survival in GBM. It is previously reported that FRA-1 can dysregulate at-least 50 genes involved in tumor invasiveness in tumor xenografts making it a therapeutic target for GBM intervention. We propose that IGFBP2 drives dysregulated gene network responsible for short survival in GBM via FRA-1 transcription factor.
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.